Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Starling Oncology's revenue for the twelve months ending Jun 30, 2026 was $587.24M, up 38.4% year over year. For fiscal 2025 it was $502.73M, up 27.8% from the year before. The highest annual figure on record is $502.73M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $502.73M | +27.8% |
| FY2024 | Dec 31, 2024 | $393.41M | +21.3% |
| FY2023 | Dec 31, 2023 | $324.24M | +28.4% |
| FY2022 | Dec 31, 2022 | $252.48M | +24.4% |
| FY2021 | Dec 31, 2021 | $203.00M | +8.3% |
| FY2020 | Dec 31, 2020 | $187.52M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $161.28M | +34.6% |
| Q1 FY2026 | Mar 31, 2026 | $147.44M | +41.2% |
| Q4 FY2025 | Dec 31, 2025 | $141.96M | +41.6% |
| Q3 FY2025 | Sep 30, 2025 | $136.56M | +36.7% |
| Q2 FY2025 | Jun 30, 2025 | $119.80M | +21.5% |
| Q1 FY2025 | Mar 31, 2025 | $104.41M | +10.3% |
| Q4 FY2024 | Dec 31, 2024 | $100.27M | +16.9% |
| Q3 FY2024 | Sep 30, 2024 | $99.90M | +21.8% |
| Q2 FY2024 | Jun 30, 2024 | $98.58M | +22.9% |
| Q1 FY2024 | Mar 31, 2024 | $94.67M | +24.2% |
| Q4 FY2023 | Dec 31, 2023 | $85.79M | +20.1% |
| Q3 FY2023 | Sep 30, 2023 | $82.04M | +26.3% |
| Q2 FY2023 | Jun 30, 2023 | $80.22M | +31.7% |
| Q1 FY2023 | Mar 31, 2023 | $76.19M | +38.1% |
| Q4 FY2022 | Dec 31, 2022 | $71.42M | +36.6% |
| Q3 FY2022 | Sep 30, 2022 | $64.98M | +24.3% |
| Q2 FY2022 | Jun 30, 2022 | $60.92M | +22.2% |
| Q1 FY2022 | Mar 31, 2022 | $55.16M | +13.5% |
| Q4 FY2021 | Dec 31, 2021 | $52.30M | – |
| Q3 FY2021 | Sep 30, 2021 | $52.28M | – |
| Q2 FY2021 | Jun 30, 2021 | $49.84M | – |
| Q1 FY2021 | Mar 31, 2021 | $48.58M | – |